Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ORIC NASDAQ:PHAR NASDAQ:TLSA NASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeORICOric Pharmaceuticals$10.23+2.0%$10.38$3.90▼$14.67$974.14M1.69763,636 shs711,532 shsPHARPharming Group$14.84+1.7%$11.31$6.73▼$17.08$999.63M0.0213,690 shs8,789 shsTLSATiziana Life Sciences$1.81-1.1%$1.83$0.63▼$2.60$213.83M-0.57416,227 shs167,938 shsUPBUpstream Bio$17.13+2.2%$13.96$5.14▼$29.46$903.52MN/A437,636 shs305,698 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceORICOric Pharmaceuticals+1.99%+5.03%-4.48%+23.85%+0.59%PHARPharming Group+1.71%+8.32%+56.19%+36.21%+98.66%TLSATiziana Life Sciences-1.09%-12.14%-23.63%+36.09%+52.10%UPBUpstream Bio+2.21%-2.84%+12.77%+87.21%+1,712,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationORICOric Pharmaceuticals4.7412 of 5 stars4.53.00.04.42.63.30.6PHARPharming Group2.3428 of 5 stars3.53.00.00.03.00.00.6TLSATiziana Life Sciences0.7681 of 5 stars0.03.00.00.03.31.70.0UPBUpstream Bio2.2988 of 5 stars3.50.00.00.03.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceORICOric Pharmaceuticals 2.90Moderate Buy$17.6372.29% UpsidePHARPharming Group 3.00Buy$30.00102.16% UpsideTLSATiziana Life Sciences 0.00N/AN/AN/AUPBUpstream Bio 3.00Buy$56.50229.83% UpsideCurrent Analyst Ratings BreakdownLatest TLSA, UPB, ORIC, and PHAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025ORICOric PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.008/14/2025ORICOric PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $19.008/13/2025ORICOric PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/12/2025ORICOric PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold7/8/2025ORICOric PharmaceuticalsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.006/23/2025ORICOric PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookORICOric PharmaceuticalsN/AN/AN/AN/A$3.34 per shareN/APHARPharming Group$339.84M2.99$0.08 per share196.82$3.50 per share4.24TLSATiziana Life SciencesN/AN/AN/AN/A$0.04 per shareN/AUPBUpstream Bio$2.37M389.65N/AN/A$7.58 per share2.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateORICOric Pharmaceuticals-$127.85M-$1.89N/AN/AN/AN/A-51.75%-47.09%11/11/2025 (Estimated)PHARPharming Group-$11.84M-$0.13N/A494.67N/A-2.19%-3.31%-1.78%10/23/2025 (Estimated)TLSATiziana Life Sciences-$11.86MN/A0.00∞N/AN/AN/AN/A10/13/2025 (Estimated)UPBUpstream Bio-$62.81MN/A0.00N/AN/A-3,836.58%-35.90%-26.26%11/6/2025 (Estimated)Latest TLSA, UPB, ORIC, and PHAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ORICOric Pharmaceuticals-$0.46-$0.47-$0.01-$0.47N/AN/A8/6/2025Q2 2025UPBUpstream Bio-$0.61-$0.74-$0.13-$0.74$0.32 million$0.94 million7/31/2025Q2 2025PHARPharming Group-$0.10$0.06+$0.16$0.06$70.36 million$93.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthORICOric PharmaceuticalsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioORICOric PharmaceuticalsN/A16.1316.13PHARPharming Group0.382.792.07TLSATiziana Life SciencesN/A1.021.02UPBUpstream BioN/A38.2738.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipORICOric Pharmaceuticals95.05%PHARPharming Group0.03%TLSATiziana Life SciencesN/AUPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipORICOric Pharmaceuticals6.82%PHARPharming Group2.07%TLSATiziana Life Sciences39.82%UPBUpstream Bio13.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableORICOric Pharmaceuticals8097.12 million90.50 millionOptionablePHARPharming Group28068.52 million67.10 millionNot OptionableTLSATiziana Life Sciences8116.85 million70.32 millionOptionableUPBUpstream Bio3853.91 million46.60 millionN/ATLSA, UPB, ORIC, and PHAR HeadlinesRecent News About These CompaniesUpstream Bio (NASDAQ:UPB) Shares Down 5.4% - What's Next?August 27 at 3:07 PM | marketbeat.comPiper Sandler bestätigt 'Overweight'-Rating für Upstream Bio und sieht deutliches KurspotenzialAugust 26, 2025 | de.investing.comUpstream Bio (NASDAQ:UPB) Shares Down 4.8% - Here's What HappenedAugust 20, 2025 | marketbeat.comUpstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, VerekitugAugust 20, 2025 | msn.comUpstream Bio (NASDAQ:UPB) Sees Unusually-High Trading Volume - Here's WhyAugust 12, 2025 | marketbeat.comQ3 EPS Estimates for Upstream Bio Cut by William BlairAugust 9, 2025 | marketbeat.comUpstream Bio Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsAugust 8, 2025 | finance.yahoo.comUpstream Bio (UPB) Q2 R&D Soars 169%August 6, 2025 | fool.comUpstream Bio, Inc. reports Q2 resultsAugust 6, 2025 | seekingalpha.comUpstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued ProgressAugust 6, 2025 | globenewswire.comUpstream Bio (NASDAQ:UPB) Stock Price Up 8.1% - Still a Buy?July 31, 2025 | marketbeat.comPromising Outlook for Upstream Bio, Inc. as Verekitug Advances in Inflammatory ConditionsJuly 28, 2025 | tipranks.comPositive Outlook for Upstream Bio, Inc. Driven by Promising Phase II Study of Verekitug in CRSwNP TreatmentJuly 28, 2025 | tipranks.comUpstream Bio Inc. (UPB) Stock Price Today - WSJJuly 25, 2025 | wsj.comUpstream Bio begins phase 2 COPD trial for verekitugJuly 10, 2025 | uk.investing.comUpstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic ...July 8, 2025 | bakersfield.comBUpstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory PortfolioJuly 8, 2025 | quiverquant.comQUpstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)July 8, 2025 | globenewswire.comUPB Upstream Bio, Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comUpstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody SpaceJune 16, 2025 | tipranks.comUpstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher PotencyJune 15, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesJoby Aviation: Why a Historic Flight Outweighs Analyst DowngradesBy Jeffrey Neal Johnson | August 19, 2025Mercury Systems Up 27%: Financials Send Investors a Clear SignalBy Jeffrey Neal Johnson | August 14, 2025Equal Weight ETFs: Hidden Upside in Today’s MarketBy Gabriel Osorio-Mazilli | August 23, 2025Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick?By Chris Markoch | August 28, 2025MarketBeat Week in Review – 08/18 - 08/22By MarketBeat Staff | August 23, 2025TLSA, UPB, ORIC, and PHAR Company DescriptionsOric Pharmaceuticals NASDAQ:ORIC$10.23 +0.20 (+1.99%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.23 0.00 (0.00%) As of 08/29/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Pharming Group NASDAQ:PHAR$14.84 +0.25 (+1.71%) Closing price 08/29/2025 03:58 PM EasternExtended Trading$14.57 -0.27 (-1.81%) As of 08/29/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Tiziana Life Sciences NASDAQ:TLSA$1.81 -0.02 (-1.09%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.85 +0.04 (+2.21%) As of 08/29/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.Upstream Bio NASDAQ:UPB$17.13 +0.37 (+2.21%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$17.80 +0.68 (+3.94%) As of 08/29/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
